Infitec Intelligence established a "Longevity Committee", with Lilly's Vice President of Discovery Chemistry appointed as chairman.

On April 22, Engsai Intelligence announced the establishment of the industry's first Longevity Committee. The committee focuses on areas including life model research, development of aging biomarkers, identification of dual-use targets related to aging, longevity, and disease, and clinical development verifying the impact of therapeutic drugs on key aging features through biomarkers and basic models. The chairman of the committee is Andrew Adams, Vice President of Molecular Discovery Group at Eli Lilly. On March 29, Engsai Intelligence announced a partnership with Eli Lilly in AI pharmaceuticals, setting a record for the highest total transaction amount in the global early pipeline authorization of AI pharmaceuticals, up to $2.75 billion.